Publications in collaboration with researchers from Shanghai Chest Hospital (2)

2016

  1. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): A phase 2B, open-label, randomised controlled trial

    The Lancet Oncology, Vol. 17, Núm. 5, pp. 577-589

2012

  1. Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer

    Journal of Clinical Oncology, Vol. 30, Núm. 25, pp. 3084-3092